Medtronic adapt study results published in the lancet diabetes & endocrinology show improved glycemic control and treatment satisfaction among those using minimed™ 780g system¹, compared to insulin injections

First-of-its-kind study demonstrates individuals using the medtronic system achieved 1.4% absolute reduction in a1c and 27.6% absolute increase in time in range dublin , sept. 1, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced results from the medtronic adapt study were published in the lancet diabetes & endocrinology.
MDT Ratings Summary
MDT Quant Ranking